Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293697 | 0.85 | LIPE (0.50) | LIPEPDCD1CD274 | |
| SCHEMBL30836614 | 0.85 | LIPE (0.50) | LIPEPDCD1CD274 | |
| SCHEMBL31108324 | 0.82 | LIPE (0.41) | LIPEPDCD1CD274BACE1MAPT | |
| SCHEMBL20293126 | 0.76 | LIPE (0.50) | LIPEPDCD1CD274MAPTSMN1; SMN2 | |
| SCHEMBL30836715 | 0.76 | LIPE (0.50) | LIPEPDCD1CD274MAPTSMN1; SMN2 | |
| SCHEMBL20293076 | 0.75 | LIPE (0.52) | LIPEBACE1SMN1; SMN2BACE2 | |
| SCHEMBL31108231 | 0.74 | KDM4E (0.38) | PDCD1CD274BACE1MAPTSMN1; SMN2 | |
| SCHEMBL31108271 | 0.73 | LIPE (0.52) | LIPEPDCD1CD274 | |
| SCHEMBL20312243 | 0.73 | LIPE (0.40) | LIPE | |
| SCHEMBL30127865 | 0.73 | LIPE (0.40) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024214088-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-10-17 | — | — | WO | disclosed |